Apophysomyces elegans: Epidemiology, amplified fragment length polymorphism typing, and in vitro antifungal susceptibility pattern

Journal of Clinical Microbiology

Volumn 48, Issue 12, 2010, Pages 4580-4585

  Chakrabarti, A ^a   Shivaprakash, M R ^a   Curfs Breuker, I ^b   Baghela, A ^a   Klaassen, C H ^b   Meis, J F ^b  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ISAVUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; ANTIFUNGAL SUSCEPTIBILITY; APOPHYSOMYCES ELEGANS; ARTICLE; BROTH DILUTION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FUNGAL STRAIN; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; OSTEOMYELITIS; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME; ZYGOMYCETES; ZYGOMYCOSIS;

ADOLESCENT; ADULT; AGED; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM ANALYSIS; ANTIFUNGAL AGENTS; CHILD; ENVIRONMENTAL MICROBIOLOGY; FEMALE; HUMANS; INDIA; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUCORALES; MUCORMYCOSIS; MYCOLOGICAL TYPING TECHNIQUES;

APOPHYSOMYCES ELEGANS; FUNGI;

EID: 78650066193     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01420-10     Document Type: Article

References (38)

1. Alastruey-Izquierdo, A., M. V. Castelli, I. Cuesta, O. Zaragoza, A. Monzon, E. Mellado, and J. L. Rodriguez-Tudela. 2009. In vitro activity of antifungals against Zygomycetes. Clin. Microbiol. Infect. 15(Suppl. 5):71-76.
2. Almyroudis, N. G., D. A. Sutton, A. W. Fothergill, M. G. Rinaldi, and S. Kusne. 2007. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob. Agents Chemother. 51:2587-2590.
3. Alvarez, E., A. M. Stchigel, J. Cano, D. A. Sutton, A. W. Fothergill, J. Chander, V. Salas, M. G. Rinaldi, and J. Guarro. 2010. Molecular phylogenetic diversity of the emerging mucoralean fungus Apophysomyces: proposal of three new species. Rev. Iberoam. Micol. 27:80-89.
4. Antachopoulos, C., J. Meletiadis, E. Roilides, T. Sein, and T. J. Walsh. 2006. Rapid susceptibility testing of medically important zygomycetes by XTT assay. J. Clin. Microbiol. 44:553-560.
5. Chakrabarti, A., S. S. Chatterjee, A. Das, N. Panda, M. R. Shivaprakash, A. Kaur, S. C. Varma, S. Singhi, A. Bhansali, and V. Sakhuja. 2009. Invasive zygomycosis in India: experience in a tertiary care hospital. Postgrad. Med. J. 85:573-581.
6. Chakrabarti, A., A. Das, J. Mandal, M. R. Shivaprakash, V. K. George, B. Tarai, P. Rao, N. Panda, S. C. Verma, and V. Sakhuja. 2006. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med. Mycol. 44:335-342.
7. Chakrabarti, A., A. Ghosh, G. S. Prasad, J. K. David, S. Gupta, A. Das, V. Sakhuja, N. K. Panda, S. K. Singh, S. Das, and T. Chakrabarti. 2003. Apophysomyces elegans: an emerging zygomycete in India. J. Clin. Microbiol. 41:783-788.
8. Chakrabarti, A., N. Panda, S. C. Varma, K. Singh, A. Das, S. C. Sharma, and A. A. Padhye. 1997. Craniofacial zygomycosis caused by Apophysomyces elegans. Mycoses 40:419-421.
9. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Dannaoui, E., J. Meletiadis, J. W. Mouton, J. F. Meis, and P. E. Verweij. 2003. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J. Antimicrob. Chemother. 51:45-52.
11. Dassanayake, R. S., and L. P. Samaranayake. 2003. Amplification-based nucleic acid scanning techniques to assess genetic polymorphism in Candida. Crit. Rev. Microbiol. 29:1-24.
12. Devi, S. C., R. Kanungo, E. Barreto, A. G. Thomas, N. Shashikala, S. Srinivasan, and P. K. Anitha. 2008. Favorable outcome of amphotericin B treatment of zygomycotic necrotizing fascitis caused by Apophysomyces elegans. Int. J. Dermatol. 47:407-409.
13. Eisen, D. P., and J. Robson. 2004. Complete resolution of pulmonary Rhizopus oryzae infection with itraconazole treatment: more evidence of the utility of azoles for zygomycosis. Mycoses 47:159-162.
14. Ferguson, T. D., S. D. Schniederjan, J. Dionne-Odom, M. E. Brandt, M. G. Rinaldi, F. S. Nolte, A. Langston, and S. M. Zimmer. 2007. Posaconazole treatment for Apophysomyces elegans rhino-orbital zygomycosis following trauma for a male with well-controlled diabetes. J. Clin. Microbiol. 45:1648-1651.
15. Guinea, J., T. Pelaez, S. Recio, M. Torres-Narbona, and E. Bouza. 2008. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob. Agents Chemother. 52:1396-1400.
16. Hoog, G. S., J. Guarro, J. Gené, and M. J. Figueras. 2000. Atlas of clinical fungi, 2nd ed. Centraalbureau voor Schimmelcultures, Utrecht, Netherlands.
17. Jain, D., Y. Kumar, R. K. Vasishta, L. Rajesh, S. K. Pattari, and A. Chakrabarti. 2006. Zygomycotic necrotizing fasciitis in immunocompetent patients: a series of 18 cases. Mod. Pathol. 19:1221-1226.
18. Johnson, E. M., A. Szekely, and D. W. Warnock. 1998. In vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J. Antimicrob. Chemother. 42:741-745.
19. Klaassen, C. H., and N. Osherov. 2007. Aspergillus strain typing in the genomics era. Stud. Mycol. 59:47-51.
20. Kondori, N., E. Svensson, and I. Mattsby-Baltzer. 2010. In vitro susceptibility of filamentous fungi to itraconazole, voriconazole and posaconazole by Clinical and Laboratory Standards Institute reference method and E-test. Mycoses doi:10.1111/j.1439-0507.2010.01913.x.
21. Lass-Florl, C., A. Mayr, S. Perkhofer, G. Hinterberger, J. Hausdorfer, C. Speth, and M. Fille. 2008. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 52:3637-3641.
22. Liang, K. P., I. M. Tleyjeh, W. R. Wilson, G. D. Roberts, and Z. Temesgen. 2006. Rhino-orbitocerebral mucormycosis caused by Apophysomyces elegans. J. Clin. Microbiol. 44:892-898.
23. Marak, R. S., R. Misra, M. S. Ansari, A. Dixit, Poornima, K. N. Prasad, and T. N. Dhole. 1 April 2010. Successful medical management of renal zygomycosis: a summary of two cases and a review of the Indian literature. Med. Mycol. [Epub ahead of print.] doi:10.3109/13693781003753477.
24. Martin de la Escalera, C., A. I. Aller, E. Lopez-Oviedo, A. Romero, A. I. Martos, E. Canton, J. Peman, P. Garcia Martos, and E. Martin-Mazuelos. 2008. Activity of BAL 4815 against filamentous fungi. J. Antimicrob. Chemother. 61:1083-1086.
25. Meis, J. F., and A. Chakrabarti. 2009. Changing epidemiology of an emerging infection: zygomycosis. Clin. Microbiol. Infect. 15(Suppl. 5):10-14.
26. Meis, J. F., B. J. Kullberg, M. Pruszczynski, and R. P. Veth. 1994. Severe osteomyelitis due to the zygomycete Apophysomyces elegans. J. Clin. Microbiol. 32:3078-3081.
27. Padhye, A. A., and L. Ajello. 1988. Simple method of inducing sporulation by Apophysomyces elegans and Saksenaea vasiformis. J. Clin. Microbiol. 26:1861-1863.
28. Page, R. L., J. Schwiesow, and A. Hilts. 2007. Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature. Pharmacotherapy 27:290-298.
29. Parthiban, K., S. Gnanaguruvelan, C. Janaki, G. Sentamilselvi, and J. M. Boopalraj. 1998. Rhinocerebral zygomycosis. Mycoses 41:51-53.
30. Perkhofer, S., V. Lechner, and C. Lass-Florl. 2009. In vitro activity of isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 53:1645-1647.
31. Pitisuttithum, P., R. Negroni, J. R. Graybill, B. Bustamante, P. Pappas, S. Chapman, R. S. Hare, and C. J. Hardalo. 2005. Activity of posaconazole in the treatment of central nervous system fungal infections. J. Antimicrob. Chemother. 56:745-755.
32. Ribes, J. A., C. L. Vanover-Sams, and D. J. Baker. 2000. Zygomycetes in human disease. Clin. Microbiol. Rev. 13:236-301.
33. Roden, M. M., T. E. Zaoutis, W. L. Buchanan, T. A. Knudsen, T. A. Sarkisova, R. L. Schaufele, M. Sein, T. Sein, C. C. Chiou, J. H. Chu, D. P. Kontoyiannis, and T. J. Walsh. 2005. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 41:634-653.
34. Sun, Q. N., A. W. Fothergill, D. I. McCarthy, M. G. Rinaldi, and J. R. Graybill. 2002. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob. Agents Chemother. 46:1581-1582.
35. Thomas, A. J., S. Shah, M. S. Mathews, and N. Chacko. 2008. Apophysomyces elegans - renal mucormycosis in a healthy host: a case report from south India. Indian J. Med. Microbiol. 26:269-271.
36. van Burik, J. A., R. S. Hare, H. F. Solomon, M. L. Corrado, and D. P. Kontoyiannis. 2006. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin. Infect. Dis. 42:e61-e65.
37. Verweij, P. E., G. M. Gonzalez, N. P. Wiedrhold, C. Lass-Florl, P. Warn, M. Heep, M. A. Ghannoum, and J. Guinea. 2009. In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries. J. Chemother. 21:272-281.
38. Wieden, M. A., K. K. Steinbronn, A. A. Padhye, L. Ajello, and F. W. Chandler. 1985. Zygomycosis caused by Apophysomyces elegans. J. Clin. Microbiol. 22:522-526.